Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy

Masahiro Mohri, Toshihiro Ichiki, Yoshitaka Hirooka, Akira Takeshita

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Left ventricular hypertrophy (LVH) caused by chronic pressure overload is associated with increased risk of myocardial ischemia without epicardial coronary artery disease. We aimed to test the hypothesis that endogenous nitric oxide (NO) prevents myocardial ischemia in patients with LVH. Methods: Epicardial coronary blood flow (Doppler wire and quantitative coronary arteriography) and myocardial lactate metabolism (paired arterial and coronary sinus blood sampling) were measured in 12 patients with hypertension, LVH, and angiographically normal epicardial coronary arteries and in 7 control subjects. Measurements were done under 3 pacing protocols: with no treatment (control), with intracoronary NG-monomethyl-L-arginine (L-NMMA; NO synthesis inhibitor), and with intracoronary L-arginine (NO substrate). Results: In control subjects the myocardial lactate extraction ratio was normal and stable during the 3 pacing protocols. In contrast, lactate uptake was significantly decreased from 0.21 ± 0.05 to 0.10 ± 0.06 (P <.05) during L-NMMA pacing in patients with LVH; in 6 of them, lactate production was demonstrated. After L-arginine administration, the lactate extraction ratio during pacing was normalized (0.18 ± 0.04) and lactate production was not observed in any patient. The level of myocardial lactate uptake at peak pacing after L-NMMA was correlated with that under untreated condition (P <.0001). Conclusions: In patients with hypertension, LVH, and angiographically normal coronary arteries, inhibition of endogenous NO synthesis in the coronary circulation unmasked myocardial ischemia during tachycardia, and L-arginine reversed the adverse effects of L-NMMA. Although the precise mechanism remains to be determined, our results suggest that constitutive NO in the coronary circulation plays an anti-ischemic role in this population.

Original languageEnglish
Pages (from-to)684-689
Number of pages6
JournalAmerican heart journal
Volume143
Issue number4
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Left Ventricular Hypertrophy
omega-N-Methylarginine
Myocardial Ischemia
Lactic Acid
Nitric Oxide
Hypertension
Arginine
Coronary Circulation
Coronary Vessels
Coronary Sinus
Tachycardia
Coronary Artery Disease
Angiography
Pressure
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. / Mohri, Masahiro; Ichiki, Toshihiro; Hirooka, Yoshitaka; Takeshita, Akira.

In: American heart journal, Vol. 143, No. 4, 01.01.2002, p. 684-689.

Research output: Contribution to journalArticle

Mohri, Masahiro ; Ichiki, Toshihiro ; Hirooka, Yoshitaka ; Takeshita, Akira. / Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. In: American heart journal. 2002 ; Vol. 143, No. 4. pp. 684-689.
@article{57e2ca27512147129f499efa09c7bd53,
title = "Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy",
abstract = "Background: Left ventricular hypertrophy (LVH) caused by chronic pressure overload is associated with increased risk of myocardial ischemia without epicardial coronary artery disease. We aimed to test the hypothesis that endogenous nitric oxide (NO) prevents myocardial ischemia in patients with LVH. Methods: Epicardial coronary blood flow (Doppler wire and quantitative coronary arteriography) and myocardial lactate metabolism (paired arterial and coronary sinus blood sampling) were measured in 12 patients with hypertension, LVH, and angiographically normal epicardial coronary arteries and in 7 control subjects. Measurements were done under 3 pacing protocols: with no treatment (control), with intracoronary NG-monomethyl-L-arginine (L-NMMA; NO synthesis inhibitor), and with intracoronary L-arginine (NO substrate). Results: In control subjects the myocardial lactate extraction ratio was normal and stable during the 3 pacing protocols. In contrast, lactate uptake was significantly decreased from 0.21 ± 0.05 to 0.10 ± 0.06 (P <.05) during L-NMMA pacing in patients with LVH; in 6 of them, lactate production was demonstrated. After L-arginine administration, the lactate extraction ratio during pacing was normalized (0.18 ± 0.04) and lactate production was not observed in any patient. The level of myocardial lactate uptake at peak pacing after L-NMMA was correlated with that under untreated condition (P <.0001). Conclusions: In patients with hypertension, LVH, and angiographically normal coronary arteries, inhibition of endogenous NO synthesis in the coronary circulation unmasked myocardial ischemia during tachycardia, and L-arginine reversed the adverse effects of L-NMMA. Although the precise mechanism remains to be determined, our results suggest that constitutive NO in the coronary circulation plays an anti-ischemic role in this population.",
author = "Masahiro Mohri and Toshihiro Ichiki and Yoshitaka Hirooka and Akira Takeshita",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/mhj.2002.120149",
language = "English",
volume = "143",
pages = "684--689",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy

AU - Mohri, Masahiro

AU - Ichiki, Toshihiro

AU - Hirooka, Yoshitaka

AU - Takeshita, Akira

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background: Left ventricular hypertrophy (LVH) caused by chronic pressure overload is associated with increased risk of myocardial ischemia without epicardial coronary artery disease. We aimed to test the hypothesis that endogenous nitric oxide (NO) prevents myocardial ischemia in patients with LVH. Methods: Epicardial coronary blood flow (Doppler wire and quantitative coronary arteriography) and myocardial lactate metabolism (paired arterial and coronary sinus blood sampling) were measured in 12 patients with hypertension, LVH, and angiographically normal epicardial coronary arteries and in 7 control subjects. Measurements were done under 3 pacing protocols: with no treatment (control), with intracoronary NG-monomethyl-L-arginine (L-NMMA; NO synthesis inhibitor), and with intracoronary L-arginine (NO substrate). Results: In control subjects the myocardial lactate extraction ratio was normal and stable during the 3 pacing protocols. In contrast, lactate uptake was significantly decreased from 0.21 ± 0.05 to 0.10 ± 0.06 (P <.05) during L-NMMA pacing in patients with LVH; in 6 of them, lactate production was demonstrated. After L-arginine administration, the lactate extraction ratio during pacing was normalized (0.18 ± 0.04) and lactate production was not observed in any patient. The level of myocardial lactate uptake at peak pacing after L-NMMA was correlated with that under untreated condition (P <.0001). Conclusions: In patients with hypertension, LVH, and angiographically normal coronary arteries, inhibition of endogenous NO synthesis in the coronary circulation unmasked myocardial ischemia during tachycardia, and L-arginine reversed the adverse effects of L-NMMA. Although the precise mechanism remains to be determined, our results suggest that constitutive NO in the coronary circulation plays an anti-ischemic role in this population.

AB - Background: Left ventricular hypertrophy (LVH) caused by chronic pressure overload is associated with increased risk of myocardial ischemia without epicardial coronary artery disease. We aimed to test the hypothesis that endogenous nitric oxide (NO) prevents myocardial ischemia in patients with LVH. Methods: Epicardial coronary blood flow (Doppler wire and quantitative coronary arteriography) and myocardial lactate metabolism (paired arterial and coronary sinus blood sampling) were measured in 12 patients with hypertension, LVH, and angiographically normal epicardial coronary arteries and in 7 control subjects. Measurements were done under 3 pacing protocols: with no treatment (control), with intracoronary NG-monomethyl-L-arginine (L-NMMA; NO synthesis inhibitor), and with intracoronary L-arginine (NO substrate). Results: In control subjects the myocardial lactate extraction ratio was normal and stable during the 3 pacing protocols. In contrast, lactate uptake was significantly decreased from 0.21 ± 0.05 to 0.10 ± 0.06 (P <.05) during L-NMMA pacing in patients with LVH; in 6 of them, lactate production was demonstrated. After L-arginine administration, the lactate extraction ratio during pacing was normalized (0.18 ± 0.04) and lactate production was not observed in any patient. The level of myocardial lactate uptake at peak pacing after L-NMMA was correlated with that under untreated condition (P <.0001). Conclusions: In patients with hypertension, LVH, and angiographically normal coronary arteries, inhibition of endogenous NO synthesis in the coronary circulation unmasked myocardial ischemia during tachycardia, and L-arginine reversed the adverse effects of L-NMMA. Although the precise mechanism remains to be determined, our results suggest that constitutive NO in the coronary circulation plays an anti-ischemic role in this population.

UR - http://www.scopus.com/inward/record.url?scp=0036235249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036235249&partnerID=8YFLogxK

U2 - 10.1067/mhj.2002.120149

DO - 10.1067/mhj.2002.120149

M3 - Article

VL - 143

SP - 684

EP - 689

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -